Close Menu

NEW YORK – A team led by researchers at Johns Hopkins University has identified several tumor and immune system features that appear to boost checkpoint immunotherapy response predictions in lung cancer. Notably, those features include a corrected tumor mutational burden (TMB) estimate with a computational approach that takes tumor purity into account.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.